Rallybio Holdings LLC (RLYB) News

Form 8-K - Current report

Rallybio to Present at the 2024 Jones Healthcare Seaside Summit

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations

– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant...

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

- On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 - - $94.2 Million in Cash...

Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of...

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting

 - Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women - - Among HPA-1a Negative Pregnant Women...

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

- Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson & Johnson - Rallybio Corporation (Nasdaq:...